CN108653204A - A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition and preparation method thereof - Google Patents
A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN108653204A CN108653204A CN201810854765.XA CN201810854765A CN108653204A CN 108653204 A CN108653204 A CN 108653204A CN 201810854765 A CN201810854765 A CN 201810854765A CN 108653204 A CN108653204 A CN 108653204A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- polyene phosphatidylcholine
- injection
- injection liquid
- injections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition of present invention offer and preparation method thereof, the composition includes Polyene Phosphatidylcholine, methoxy poly (ethylene glycol) phosphatidyl-ethanolamine, N tri- (methylol) methylglycine, arginine, cholesterol, water for injection, soybean oil, antioxidant etc., it will not become cloudy when Clinical practice is diluted, the safety for improving clinical application improves the compliance of patient medication.
Description
Technical field
The present invention relates to a kind of Polyene Phosphatidylcholine injection liquid pharmaceutical compositions and preparation method thereof, and the invention belongs to drugs
The scope of formulation art.
Background technology
Polyene Phosphatidylcholine is a kind of lecithin in high purity extracted from soybean lecithin, containing a large amount of
Unsaturated fatty acid, predominantly linoleic acid (accounting for about 70%), leukotrienes and oleic acid, due to being rich in a variety of unsaturated fatty acids, therefore
Referred to as Polyene Phosphatidylcholine." required " phosphatide that Polyene Phosphatidylcholine behaviour cannot synthesize in vivo, is a kind of liver plasma membrane
Protective agent can treat a variety of acute and chronic liver diseases.There is liver plasma membrane and damaged with cell mitochondrial ultra microstructure in various hepatopathys
Hinder and synthesize deficiency with energy with phosphatide loss and cellular respiration, takes supplemented with exogenous phosphatide, unsaturated phosphatide is introduced
In liver plasma membrane structure, endogenous saturated phospholipid is substituted, membrane fluidity can be made to enhance with transmembrane transport system activity, impaired film
Structure is therefore restored.Polyene Phosphatidylcholine is the hepatic of current curative effect more certainly.Injection is the drug
Major Clinical application forms.
CN1602878A provides a kind of Polyene Phosphatidylcholine injection liquid, and auxiliary material is related to sodium taurocholate, NaTDC, dehydrogenation
Sodium taurocholate, benzyl alcohol etc..CN1781488A provides a kind of polyene phosphatidyl choline infusion solution, auxiliary material be related to xylitol, glucose,
Vitamin, sodium pantothenate, niacinamide, poloxamer, deoxycholic aicd, polyoxyethylene (40) castor oil, antioxidant, isotonic agent sodium chloride
Deng.CN1961886A provides a kind of Polyene Phosphatidylcholine injection liquid, and auxiliary material is related to sodium taurocholate, NaTDC, neocholan
Sodium, preservative, antioxidant etc..CN101244070A provides a kind of polyene phosphatidylcholine high-capacity injection, wherein cosolvent
Selected from deoxycholic acid, sodium hydroxide, absolute ethyl alcohol, isotonic agent is selected from glucose, xylitol, mannitol, sorbierite, dextrose
Acid anhydride, antioxidant select vitamin E etc..CN101756895A provides a kind of polyene phosphatidyl choline intravenous preparation, and auxiliary material includes
Sodium taurocholate, xylitol.CN101152189A provides a kind of Polyene Phosphatidylcholine injection liquid, auxiliary material include benzyl alcohol, cholic acid,
Tween, ethyl alcohol, propylene glycol, glycerine, sodium hydroxide, sodium carbonate and antioxidant 2,6-di-tert-butyl p-cresol, tertiary butyl-
4-HA, vitamin E etc..CN101669902A provides a kind of polyene phosphatidyl choline injection, and auxiliary material is main
Including solubilizer and preservative, wherein solubilizer is selected from sodium taurocholate, NaTDC, natrium dehydrocholicum；Preservative is benzyl alcohol.
CN102631313A provides a kind of polyene phosphatidyl choline intravenous drug-delivery preparation, is made of drug solution agent and assisted solution agent,
Its injection organic solvent is selected from polyethylene glycol, propylene glycol, glycerine, absolute ethyl alcohol etc., and stabilizer is selected from vitamin E, butyl hydroxyl
Base anisole, citric acid, EDTA-2Na etc., cosolvent are Cholic acids, and isotonic regulator is selected from glycerine, sorbierite, mannitol, Portugal
Grape sugar etc..CN103705446A provides a kind of Polyene Phosphatidylcholine injection liquid, contains solubilizer, preservative and stabilizer, wherein
Solubilizer is selected from deoxycholic aicd, deoxysodium cholate, neocholan, natrium dehydrocholicum, cholic acid or sodium taurocholate, and stabilizer is selected from amino
Acid or its sodium salt or trishydroxymethylaminomethane.CN104080460A provides a kind of courage containing phosphatidyl without NaTDC
The Injectable composition of alkali, it includes phosphatidyl choline, ethyl alcohol, propylene glycol and/or benzylalcohol, polysorbate and/or polyethylene glycol
15- hydroxy stearic acid esters；And the water or water for injection of surplus.CN103816118A provides a kind of Polyene Phosphatidylcholine injection
With composition, with Polyene Phosphatidylcholine and methoxy poly (ethylene glycol)-phosphatidyl-ethanolamine, cholesterol, water for injection, soybean
Oil, glycine-HCl buffer solutions are raw material, are prepared by compound compatibility.CN105997854A provides a kind of polyenoid phosphatide
Phatidylcholine injecta composition, by Polyene Phosphatidylcholine, benzyl alcohol, butylhydroxy anisole, 2,6- di-t-butyls to first
Phenol, cholic acid, ethyl alcohol, sodium hydroxide, water for injection composition.
Polyene Phosphatidylcholine is phospholipid drug, contains the hydrophilic segments such as phosphoric acid, choline in molecule, and contain aliphatic acid
Chain hydrophobic part, belongs to surface reactive material, has a series of interfaces and colloidal nature, and such as Interfacial Adsorption forms micelle, lipid
Body and emulsification etc..Polyene Phosphatidylcholine is oxidizable, quick to light and heat due to being rich in a variety of unsaturated fatty acids
Sense is not soluble in water as other phosphatide, but may expand in water, is in colloidal solution, and properties of Aqueous Solution is not easy to stablize.
Polyene Phosphatidylcholine injection liquid is the higher yellow clarified solution body of concentration, 5% Portugal of generally use when clinical application
Intravenously administrable after the dilution of grape sugar juice, but occur muddy phenomenon in being diluted process for preparation and occur, lead to drug not
It can use.This phenomenon be due to the properties of Aqueous Solution of Polyene Phosphatidylcholine itself be not easy stablize caused by, there is presently no
Good solution, such as commercially available Polyene Phosphatidylcholine injection liquid (Essentiale N/Essentiale Forte N) also only warn in its specification " only
Clear solution can be used "；Above-mentioned prior art patent is also without reference to the solution of this problem.Therefore, for existing polyenoid phosphorus
Phosphatidylcholine injection, it is current this field urgent problem to be solved to occur muddiness when Clinical practice is diluted.
Invention content
Inventor passes through a large amount of formulation study and validation trial, obtains a kind of Polyene Phosphatidylcholine injection liquid medicine
Compositions can well solve Polyene Phosphatidylcholine injection liquid and muddy problem occur in dilution.
The technical scheme is that：
A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition is provided, is contained per 10L injections：
Further, the Polyene Phosphatidylcholine injection liquid pharmaceutical composition contains per 10L injections：
In one embodiment, the Polyene Phosphatidylcholine injection liquid pharmaceutical composition contains per 10L injections：
In another embodiment, the Polyene Phosphatidylcholine injection liquid pharmaceutical composition contains per 10L injections：
The present invention also provides the preparation methods of the Polyene Phosphatidylcholine injection liquid pharmaceutical composition：By the more of recipe quantity
It is molten with ultrasound after alkene phosphatidyl choline, methoxy poly (ethylene glycol)-phosphatidyl-ethanolamine, cholesterol, soybean oil, antioxidant mixing
Solution, solution temperature control is at 40 DEG C hereinafter, adding N- tri- (methylol) methylglycine of recipe quantity, arginine and always matching liquid
The water for injection of amount 40%, stirring is to clear liquid, needle-use activated carbon coarse filtration, and benefit adds water to enough, stirs evenly, miillpore filter
Filtration, filling in ampoule after passed examination, nitrogen charging sealing, sterilizing to get.
The one kind or more of antioxidant described above in vitamin E, vitamin C, 2,6 di tert butyl 4 methyl phenol
Kind.
It is stable yellow by Polyene Phosphatidylcholine injection liquid pharmaceutical composition prepared by above-mentioned technical proposal of the present invention
Clear liquid, detection plus product characteristics, pH value, content and related object after activated carbon adsorption is front and back and sterilizing in preparation process
Matter has no significant change, and illustrates that filtering and disinfecting action all have no significant effect Polyene Phosphatidylcholine in the present invention；By right
Product of the present invention carries out study on the stability and (places 10 under 4500Lx ± 500Lx intensities of illumination and under the conditions of 40 DEG C of high temperature respectively
It), the results showed that, the character of Polyene Phosphatidylcholine injection liquid pharmaceutical composition of the present invention, pH value, content and related substance are equal
Without significant change；Long-time stability investigate (18 months at 2~8 DEG C of storage requirement) These parameters also without significant change, illustrate this
Invention product has good stability.
Polyene Phosphatidylcholine injection liquid pharmaceutical composition prepared by the present invention is with water for injection or 5% glucose injection
Liquid will not become cloudy when diluting, and gained dilution is still the yellow clear liquid of stabilization；With difference pH degree within the scope of pH2-9
5% glucose solution of water or difference pH degree dilutes, and is equally not in turbid phenomenon, the equal clear of dilution, no particle
Object generates.
Inventor has found under study for action, N- tri- (methylol) methylglycine of specific proportioning, it is arginic be added for
It is critically important to solve present invention problem, turbid phenomenon is all easy when lacking one of which dilution；And arginine with
The weight ratio of N- tri- (methylol) methylglycine is 1:1-1:It is proper in 6 ranges, can also it go out when beyond this range dilution
Existing muddiness.
For example, by Polyene Phosphatidylcholine 30g, methoxy poly (ethylene glycol)-phosphatidyl-ethanolamine 1.5g, cholesterol 2g, N-
Three (methylol) methylglycine 1.5g, arginine 0.75g, water for injection 250mL, soybean oil 200mL, bis- uncles of antioxidant 2,6-
The prescription of butyl -4- methylphenols 250mg prepares injection 500mL；It takes 10mL injections to be diluted experiment every time, uses respectively
5% glucose injection, water for injection, 5% glucose solution of difference pH degree within the scope of pH2-9, difference pH within the scope of pH2-9
The water of degree dilutes 5 times, and obtained dilution does not occur muddiness, and solution is still the clarified solution of yellow transparent after placing 3 days, is stablized
Property is good.
In upper example, if removing N- tri- (methylol) methylglycine, remaining is constant, carries out same dilution test, then exists
There is turbid phenomenon in most of experiment；If removing arginine, remaining is constant, carries out same dilution test, then also exists
Occurs turbid phenomenon in part test.
In upper example, the amount of N- tri- (methylol) methylglycine is changed to 0.5g (arginine is still 0.75g), remaining is not
Become, turbid phenomenon occurs in most of dilution test；Arginic amount is changed to 0.2g, and (N- tri- (methylol) methyl is sweet
Propylhomoserin is still 1.5g), remaining is constant, then turbid phenomenon occurs in part of dilution experiment.
Commercially available Polyene Phosphatidylcholine injection liquid (Essentiale N/Essentiale Forte N) is taken, same dilution test above, part of dilution are carried out
Also there is apparent turbid phenomenon in liquid；If appropriate arginine and N- tri- (methylol) methylglycine are first added into Essentiale N/Essentiale Forte N
(the two weight ratio 1:4) same dilution test is carried out after again, then all dilutions do not occur muddiness.
It can be seen that (methylol) methylglycines of N- tri- and arginine and their specific proportioning, to polyenoid phosphatide
Phatidylcholine injection does not become cloudy when diluting and plays an important role.
Polyene Phosphatidylcholine injection liquid pharmaceutical composition provided by the invention and preparation method thereof has the following advantages：
1. Polyene Phosphatidylcholine injection liquid pharmaceutical composition clarity made from is good, and stability is high, with water for injection
Or when 5% glucose solution dilution, do not occur muddiness, Clinical practice is safer；
2. preparing overall process without nitrogen protection, production technology is simple and easy to do, it is easy to accomplish industrialization.
Specific implementation mode
The preparation of 1 Polyene Phosphatidylcholine injection liquid pharmaceutical composition of embodiment
Prepare the prescription of 10L Polyene Phosphatidylcholine injection liquid pharmaceutical compositions：
Preparation method：By the Polyene Phosphatidylcholine of above-mentioned recipe quantity, methoxy poly (ethylene glycol)-phosphatidyl-ethanolamine, courage
Sterol, soybean oil, antioxidant 2 use ultrasonic dissolution, solution temperature to control at 40 DEG C after the mixing of 6- di-tert-butyl-4-methy phenols
Hereinafter, N- tri- (methylol) methylglycine, arginine and the 4L waters for injection of recipe quantity are added, stirring to clear liquid,
Needle-use activated carbon coarse filtration, benefit adds water to enough, stirs evenly, miillpore filter filtration, filling in ampoule after passed examination, fills
Nitrogen seal, sterilizing to get.
The preparation of 2 Polyene Phosphatidylcholine injection liquid pharmaceutical composition of embodiment
Prepare the prescription of 10L Polyene Phosphatidylcholine injection liquid pharmaceutical compositions：
Preparation method：By the Polyene Phosphatidylcholine of above-mentioned recipe quantity, methoxy poly (ethylene glycol)-phosphatidyl-ethanolamine, courage
Ultrasonic dissolution is used after sterol, soybean oil, antioxidant vitamins C mixing, solution temperature control is at 40 DEG C hereinafter, adding recipe quantity
N- tri- (methylol) methylglycine, arginine and 4L waters for injection, stirring is to clear liquid, needle-use activated carbon coarse filtration, mends
Add water to enough, stir evenly, miillpore filter filtration, after passed examination, filling in ampoule, nitrogen charging sealing, sterilizing to get.
The preparation of embodiment 3-8 Polyene Phosphatidylcholine injection liquid pharmaceutical compositions
Each embodiment prescription is (10L Polyene Phosphatidylcholine injection liquids pharmaceutical composition is made altogether) as shown in the table：
Antioxidant wherein in embodiment 3,8 is vitamin C, and the antioxidant in embodiment 4,5 is 2,6- di-t-butyls -4-
Methylphenol, the antioxidant in embodiment 6,7 are vitamin E.
Preparation method is the same as embodiment 1.
The clarity of 1 dilution of test example is investigated
To the Polyene Phosphatidylcholine injection liquid pharmaceutical composition sample of the preparation of above-described embodiment 1,3,5,8, according to aforementioned
Polyene Phosphatidylcholine injection liquid sample (previously prepared) and commercially available polyenoid prepared by each prior art patent Example 1
Phosphatidyl choline injection (Essentiale N/Essentiale Forte N) sample, with 5% glucose injection, 5% glucose of water for injection, difference pH degree
5 times of dilutions of water (tri- pH degree of pH2, pH6, pH9) progress of solution (tri- pH degree of pH2, pH6, pH9), difference pH degree, are investigated dilute
Release the clarity of liquid.As a result as follows：
As can be seen from the above table, the Polyene Phosphatidylcholine injection liquid pharmaceutical composition that prepared by the present invention is with water for injection
Or when 5% glucose injection dilution be not in muddiness, gained dilution is still stable yellow clear liquid；Use pH2-
5% glucose solution of the water of difference pH degree or difference pH degree dilutes in 9 ranges, is equally not in turbid phenomenon, dilution
Equal clear, no particulate matter generate；And the Polyene Phosphatidylcholine injection liquid of the prior art then has many appearance in dilution
Muddy phenomenon occurs.
Claims (6)
1. a kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition, it is characterised in that contain per 10L injections：
2. pharmaceutical composition as described in claim 1, it is characterised in that contain per 10L injections：
3. pharmaceutical composition as claimed in claim 2, it is characterised in that contain per 10L injections：
4. pharmaceutical composition as claimed in claim 2, it is characterised in that contain per 10L injections：
5. the composition for injection as described in claim 1-4 is any, it is characterised in that the antioxidant is selected from vitamin E, dimension
It is one or more in raw element C, 2,6 di tert butyl 4 methyl phenol.
6. the preparation method of the Polyene Phosphatidylcholine injection liquid pharmaceutical composition described in claim 1-5, it is characterised in that press
It is prepared by following method：By the Polyene Phosphatidylcholine of recipe quantity, methoxy poly (ethylene glycol)-phosphatidyl-ethanolamine, cholesterol, soybean
Ultrasonic dissolution is used after oil, antioxidant mixing, solution temperature control is at 40 DEG C hereinafter, adding N- tri- (methylol) first of recipe quantity
Base glycine, arginine and total water for injection for matching liquid measure 40%, are stirred to clear liquid, needle-use activated carbon coarse filtration adds water
To enough, stir evenly, miillpore filter filtration, filling in ampoule after passed examination, nitrogen charging sealing, sterilizing to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810854765.XA CN108653204B (en) | 2018-08-01 | 2018-08-01 | Polyene phosphatidyl choline injection pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810854765.XA CN108653204B (en) | 2018-08-01 | 2018-08-01 | Polyene phosphatidyl choline injection pharmaceutical composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108653204A true CN108653204A (en) | 2018-10-16 |
| CN108653204B CN108653204B (en) | 2022-04-08 |
Family
ID=63788745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810854765.XA Active CN108653204B (en) | 2018-08-01 | 2018-08-01 | Polyene phosphatidyl choline injection pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108653204B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152189A (en) * | 2007-10-12 | 2008-04-02 | 成都翰朗生物科技有限公司 | Polyene phosphatidyl choline injection and method for preparing the same |
| CN102631313A (en) * | 2011-11-10 | 2012-08-15 | 上海天氏利医药科技有限公司 | Polyene phosphatidyl choline intravenous administration preparation and preparation method thereof |
| CN103705446A (en) * | 2012-10-08 | 2014-04-09 | 正大天晴药业集团股份有限公司 | Polyene phosphatidyl choline injection, and preparation method thereof |
| CN103816118A (en) * | 2014-02-14 | 2014-05-28 | 西藏海思科药业集团股份有限公司 | Polyene phosphatidyl choline composition for injection and preparation method thereof |
-
2018
- 2018-08-01 CN CN201810854765.XA patent/CN108653204B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152189A (en) * | 2007-10-12 | 2008-04-02 | 成都翰朗生物科技有限公司 | Polyene phosphatidyl choline injection and method for preparing the same |
| CN102631313A (en) * | 2011-11-10 | 2012-08-15 | 上海天氏利医药科技有限公司 | Polyene phosphatidyl choline intravenous administration preparation and preparation method thereof |
| CN103705446A (en) * | 2012-10-08 | 2014-04-09 | 正大天晴药业集团股份有限公司 | Polyene phosphatidyl choline injection, and preparation method thereof |
| CN103816118A (en) * | 2014-02-14 | 2014-05-28 | 西藏海思科药业集团股份有限公司 | Polyene phosphatidyl choline composition for injection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨惠等: ""多烯磷脂酰胆碱注射液配伍禁忌的文献分析"", 《中国药师》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108653204B (en) | 2022-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102448441B (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
| WO2022160971A1 (en) | Concentrate containing poorly soluble drug, and emulsion prepared therefrom | |
| EA005589B1 (en) | Clear aqueous anaesthetic composition | |
| KR20070113711A (en) | Anti-wrinkle cosmetic composition encapsulating idebenone with nano sizes and its manufacturing method | |
| RU2257892C2 (en) | Propofol stable clear compositions | |
| CN108289846A (en) | The preparation method of liposome | |
| Bjerregaard et al. | Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin | |
| US20230157309A1 (en) | Sunflower phospholipid composition containing phosphatidylcholine | |
| CN107049941A (en) | Fat emulsion containing prostaglandin | |
| US8680061B2 (en) | Medicinal forms of phospholipid preparations and methods for their preparation | |
| KR101713219B1 (en) | Injectable composition comprising phosphatidycholine and lysophosphatidylcholine, and manufacturing method thereof | |
| CN110876719B (en) | Vitamin K1 injection and preparation method thereof | |
| CN101204373A (en) | Paclitaxel lipid microspheres injection and preparation method thereof | |
| CN108653204A (en) | A kind of Polyene Phosphatidylcholine injection liquid pharmaceutical composition and preparation method thereof | |
| CN105560182B (en) | Injection Cabazitaxel composition and preparation method thereof | |
| WO2007020505A2 (en) | Medicinal forms of phospholipid preparations and methods for their preparation | |
| CN104080460A (en) | Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparation method thereof | |
| RU2605616C1 (en) | Liposomal agent based on ubiquinol and preparation method thereof | |
| CN101711739B (en) | Oral medicament combination of carbamazepine | |
| CN112870160A (en) | Novel fat-soluble vitamin mixed micelle injection and preparation method thereof | |
| CN102038636B (en) | Taxane medicine solution containing chelating agent and preparation method thereof | |
| CN101590029B (en) | Propofol composition | |
| CN107137351B (en) | Stable alprostadil emulsion injection | |
| CN107184550B (en) | Preparation method of alprostadil injection | |
| Ho et al. | Preparation and in vivo pharmacokinetic evaluation of stable microemulsion system of cholecalciferol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201229 Address after: 620010 No.53, south section of Shunjiang Avenue, East District, Meishan Economic Development Zone, Sichuan Province Applicant after: Haisike Pharmaceutical (Meishan) Co.,Ltd. Address before: 125107 Cao City Industrial Park, Xingcheng, Huludao, Liaoning Applicant before: LIAONING HAISCO PHARMACEUTICAL GROUP Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |